Company: LCTX
Filing Date: 2025-11-12
Form Type: 424B3
Source: 0001193125-25-276229
Chunk: 1

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 424B3
Chunk 1
---
 B. Riley is not required to sell any specific number or dollar amount of securities, but will act as a sales agent in connection with agency transactions using commercially reasonable efforts to sell on our behalf all of the common shares requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between B. Riley and us. In addition, B. Riley may act as principal in connection with any principal transactions. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. B. Riley will be entitled to a commission of up to 3.0% of the gross sales price per share sold under the sales agreement. In connection with the sale of the common shares on our behalf, B. Riley will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of B. Riley will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to B. Riley with respect to certain liabilities, including liabilities under the Securities Act. We are also obligated to pay a former placement agent a cash fee of 6.0% of any gross proceeds we receive from the sale of any common shares under this prospectus supplement, the Prior Supplement and the Base Prospectus in block transactions to certain entities in which common shares are sold on or before November 13, 2025. Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading “Risk Factors” on page S-4 of the Prior Supplement and under similar headings in the other documents that are incorporated by reference into the Prior Supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.